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Abstract Cervical, endometrial, ovarian, vulvar, and vaginal cancers affect women of a broad 
age spectrum. Many of these women are still sexually active when their cancer is 
diagnosed. Treatment options for gynecological malignancies, such as gynecological 
surgery, radiation, and chemotherapy, are proven risk factors for pelvic floor 
dysfunction. The prevalence of urinary incontinence, fecal incontinence, and sexual 
dysfunction before cancer treatment is still unclear. Hypotheses have been raised in the 
literature that these manifestations could represent early symptoms of pelvic cancers, but 
most remain overlooked even in cancer surviving patients.  
The primary focus of therapy is always cancer eradication, but as oncological and 
surgical treatment options become more successful, the number of cancer survivors 
increases. The quality of life of patients with gynecological cancers often remains an 
underrated subject. Pelvic floor disorders are not consistently reported by patients and 
are frequently overlooked by many clinicians. In this brief review we discuss the 
importance of pelvic floor dysfunction in patients with gynecological malignant tumors.     
Keywords  gynecological cancers, pelvic floor disorders, urinary incontinence 
  
Highlights 
 
✓ pelvic floor disorders are not consistently reported by patients and are frequently 
overlooked by many clinicians  
✓ a comprehensive care in gynecological cancer surviving women should be 
handled by a multidisciplinary team of specialists in order to improve overall 
quality of life in these patients         
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Introduction 
Women with pelvic floor dysfunction experience a 
multitude of symptoms that negatively affect their 
quality of life. Urinary incontinence, pelvic organ 
prolapse, sexual dysfunction, fecal incontinence, and 
various pain syndromes are most commonly 
encountered in these patients. In the general population 
of healthy non-pregnant women, the overall prevalence 
of pelvic floor disorders varies between 30% and 50% 
depending on the criteria and definitions applied. The 
prevalence increases with age and is more frequent in 
older women. Incontinence and sexual dysfunction are 
often seen as problems of old age. Due to many reasons, 
either social barriers or preconceptions, many women do 
not talk about these problems with their physician (1). 
Pelvic dysfunction is common in women with 
different types of cancer, especially with cervical, 
endometrial, vulvar, vaginal, ovarian, fallopian tube, 
and primary peritoneal tumors. These disorders can be 
caused directly by cancer involving pelvic organs, but 
more often they are side effects of cancer treatment. 
Sometimes, cancer invades retroperitoneal organs, 
especially the ureters, causing direct invasion or 
compression. Furthermore, this can affect renal function 
(1-5). Treatment options that can be risk factors for 
pelvic dysfunctions are radiotherapy, surgery, 
chemotherapy, and hormonal treatment. These 
treatments exert both direct and indirect effects resulting 
in functional anatomy, neurological, vascular, and 
myofascial alterations (6, 7).  
Each of the five main types of gynecological 
cancers (cervical, uterine, ovarian, vulvar, and vaginal) 
has its symptoms, its risk factors, and its burden (8), with 
a variety of specific or non-specific symptoms or even 
paraneoplastic symptoms (9). 
In the past decade, researchers presumed that pelvic 
floor dysfunction was present in women who were 
suspected for gynecological malignancy prior to the 
time of surgery. Many of these women just dealt with 
the dysfunction, despite the fact that it lowered their 
quality of life. In fact, the quality of life took a second 
place, the main objective being cancer eradication. 
Pelvic floor disorders persisted or worsened in some of 
the surviving patients after cancer treatment, but the 
issue has been poorly investigated (10, 11). 
Despite efforts in screening and prevention, the 
incidence of gynecological cancer will continue to grow 
over the next decades. Hopefully, the advances in 
treatment may decrease the mortality rate (12). As stated 
by many literature studies, the prognosis of localized 
gynecologic tumors in developed countries is excellent, 
with 5-year survival rates over 90%. Radical pelvic 
surgery is critically important in the management of 
these cancers, but it comes with the risk of urological 
complications. Ureters can be injured during surgery, 
and lymph node dissection and extensive surgery can 
damage pelvic nerves, blood vessels, and pelvic floor 
muscles, resulting in low urinary tract dysfunction (13-
16). 
Understanding pelvic floor dysfunction in women 
with suspected gynecological malignancies is limited. 
The prevalence of such disorders before surgery is also 
poorly investigated (17). Moreover, the impact of 
gynecological oncological treatment of pelvic floor 
disorders is not well understood and frequently remains 
undiscussed with oncologic patients. Our aim in this 
review is to highlight the importance of pelvic floor 
dysfunction in women with suspected gynecologic 
cancer and also in women who have received cancer 
treatment. 
 
Discussion 
Pelvic floor disorders in women suspected of 
gynecological cancers 
In 2012, the European Agency for Research on 
Cancer (EUCAN) (18) reported the following estimated 
incidence and mortality in Europe and Romania for 
three of the most frequent gynecological malignancies 
(Table 1) (18, 19). 
  
Table 1. Estimated incidence of gynecologic cancers 
in Europe and Romania, 2012 
Cancer 
type 
Estimated 
incidence in 
Europe (%) 
Estimated 
incidence in 
Romania (%) 
Corpus uteri 6.16 4.32 
Cervix uteri 3.64 12.20 
Ovary 4.08 5.20 
 
The estimated mortality for the same types of 
cancers in Europe and Romania are shown in Table 2 
(18, 19). 
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Table 2. Estimated mortality of gynecologic cancers 
in Europe and Romania, 2012 (18,19). 
Cancer 
type 
Estimated 
mortality in 
Europe (%) 
Estimated 
mortality in 
Romania (%) 
Corpus uteri 3.05 1.85 
Cervix uteri 3.13 9.85 
Ovary 5.48 5.26 
  
In 2012, Romania held first place amongst 
European countries in the estimated incidence and 
mortality for cervical cancer (18-20). 
Siegel et al. report that in 2016 more than 100.000 
women were diagnosed with gynecological cancers in 
the US. Although cancer diagnosis and eradication 
remain the primary focus of care, the prevalence of 
pelvic floor dysfunction manifesting as urinary 
incontinence and other bladder and bowel disorders at 
baseline, before patients received surgery, is unclear 
(21). 
Bretschneider et al. investigated the existence of 
pelvic floor dysfunction in 152 patients with presumed 
gynecologic malignancy prior to surgery. Overall 
prevalence of urinary incontinence was 40.9%, among 
which stress incontinence was 33.3% and urge 
incontinence was 25%. Fecal incontinence was found in 
3.9% of cases. The authors concluded that pelvic floor 
disorders are frequent in women suspected of 
gynecologic cancers and should not be overlooked (17).  
Ramasheshan et al. studied the prevalence of pelvic 
floor disorders in a systematic review of the literature. 
The research also focused on specific types of 
malignancy. In patients with cervical cancer, stress 
urinary incontinence was noted in 24-29% of cases, 
urinary incontinence in 8-18%, and fecal incontinence 
in 6% of cancer patients before treatment. In patients 
with uterine cancer, the pre-treatment prevalence of 
stress urinary incontinence was 29-36%, of urge urinary 
incontinence15-25%, and of fecal incontinence 3% (22). 
The authors also investigated the prevalence of pelvic 
floor dysfunction in cancer survivors after treatment, as 
described further in this article. 
Thomas et al. found prolapse in 7% of patients with 
endometrial cancer prior to treatment (23). 
The importance of pelvic floor dysfunction as an 
early symptom of gynecological malignant tumors was 
also hypothesized and investigated in women with 
ovarian cancer. Due to the poor survival outcomes of 
advanced ovarian cancer, early diagnostic strategies are 
continuously investigated. Researchers have explored 
the potential of using patient-reported symptoms as a 
screening tool to promote early detection.  Several 
symptom indices have been tested, among which the 
most widely evaluated is the Goff index. Goff et al. 
found that women with ovarian cancer frequently 
reported non-specific symptoms prior to diagnosis and 
thus proposed their initial index in 2007 (24). The 
original index included pelvic/abdominal pain, 
increased abdominal size/bloating, and difficulty in 
eating/feeling full. The modified index introduced by 
Kim et al. added two urinary symptoms, urgency and 
frequency, although their predictive role in ovarian 
malignancy was inconsistent (25). Shetty et al. 
investigated the predictive value of symptoms in ovarian 
cancer including frequency, urgency, and other urinary 
symptoms and noted that these symptoms were more 
frequently reported by ovarian cancer patients as 
compared to controls at 3 to 14 months before cancer 
diagnosis (26). Further investigations are needed to 
determine the significance of this particular symptom 
cluster. 
Pelvic floor disorders after cancer treatment 
Pelvic floor dysfunction in gynecological cancer 
survivors is common; it can be caused by the cancer 
itself, but mostly it is the sequelae of treatment. It 
manifests as urinary incontinence, other bladder storage 
and voiding difficulties, fecal incontinence, pelvic pain, 
and sexual problems (27, 28). Cancer treatment options 
include radical surgery, radiotherapy, chemotherapy, or 
hormonal medication, all of which come with specific 
negative outcomes. Radical hysterectomy and 
radiotherapy disrupt the anatomy of the pelvic floor and 
the local nerve supply to the pelvic floor muscles. 
Bladder and bowel symptoms are common among 
cancer survivors, and these may persist long after 
treatment and adversely affect quality of life (13, 19, 
20).  
Rutledge et al. noted that 67% of women who 
survived disease and were treatment free for more than 
a year reported moderate to severe urinary incontinence 
(29). Manchana et al. reported that up to two-thirds of 
cervical cancer survivors after radical hysterectomy had 
urodynamic abnormalities. Half of them had voiding 
dysfunction and one-third had storage dysfunction (30).  
Hazewinkel et al. reported stress incontinence after 
radical hysterectomy and lymph node dissection in 19-
81% of patients. Moreover, they found that surgery with 
adjuvant radiotherapy as compared to surgery alone had 
two times more severe urological complications and that 
primary radiotherapy was associated with increased 
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urgency to void and fecal incontinence in 8-67% of 
cases (31). 
Ramaseshan et al. performed a systematic review of 
31 articles to investigate the prevalence of pelvic floor 
dysfunction in women with gynecological cancers, 
according to the specific types of malignancy. They also 
compared the prevalence of pelvic floor dysfunction 
with the general population. In women with cervical 
cancer, they noted a 4-76% post-treatment prevalence of 
stress urinary incontinence, a 4-59% post-treatment 
prevalence of urge incontinence, and a 2-34% 
prevalence of fecal incontinence. Cervical cancer 
treatment also caused urinary retention 0.4-39% and 
dyspareunia 7-39% (22).  
Some researchers noted that urinary incontinence 
rates tended to be highest in the early post-operative 
period. Ceccaroni et al. found a urinary incontinence 
rate of 55% at 1 month after surgery (32), while Naik et 
al. found urinary incontinence rates of 48% and 17% 
respectively at 1.5 months and after 12 months after 
surgery (33).  
In patients with uterine cancer, urinary incontinence 
affected 15% of women who underwent surgery only, 
and 43% of women who underwent surgery plus 
external beam radiation therapy (EBRT). The study by 
Nosti et al. was the only study that evaluated prolapse in 
women with endometrial cancer after surgery. They 
found pelvic organ prolapse in 44% of 25 women with 
endometrial cancer at more than 6 months after surgery 
(34).  
Ovarian cancer survivors had a prevalence of stress 
urinary incontinence of 32%-42%, urge urinary 
incontinence 15%-39%, prolapse 17% and sexual 
dysfunction 62-75%. Data regarding pelvic floor 
disorders in ovarian cancer survivors are limited, 
probably because the majority of patients are diagnosed 
in advanced stages III/IV which are associated with 5-
year survival rates of only 20-35% (13, 20). 
Vulvar cancer survivors had a post-treatment 
prevalence of 15-39% for stress urinary incontinence 
and 1-20% for fecal incontinence (19, 34). 
Gynecological cancer and treatment procedures 
have a severe impact on sexual health, on body image, 
and on fertility. Sexual morbidity is also an undertreated 
issue in cancer survivorship, as found in a growing 
number of studies (27, 28). Coady et al. found that up to 
55% of women treated for gynecological cancer report 
dyspareunia (35-37).  
In their study on sexual function in women and girls 
with cancer, Lindau et al. noted that the majority of 
women affected by gynecologic and breast cancer were 
sexually active in the year prior to diagnosis, including 
the majority of older women aged 60 to 80 who have a 
partner. The authors raised the awareness about the need 
for preservation of sexual function and improvement of 
quality of life in such patients (38-40). 
Lindgren et al. investigated how gynecological 
cancer survivors relate their incontinence to their quality 
of life, and how much information they had regarding 
pelvic muscle training and other strategies to improve 
their situation. The results showed a reduction in 
physical and psychosocial quality of life and in sexual 
activity due to incontinence. Moreover, many women 
did not know about pelvic floor therapy and how it might 
improve their situation (41, 42).  
 
Conclusions 
Pelvic floor disorders are widely encountered in 
women who survive gynecological cancers, and an 
increasing body of evidence shows that these problems 
are present at baseline, before initiation of cancer 
therapy. Because the primary focus in therapy is cancer 
eradication, pelvic floor disorders are frequently 
overlooked by both patients and specialists, although 
they have a major impact on patients’ quality of life. 
Future research should focus on improving quality of 
life in cancer survivors using treatments that cause less 
damage to the pelvic floor compartment. Moreover, 
screening for pelvic floor disorders should be performed 
more often in patients suspected or already diagnosed 
with gynecological cancer.  
We conclude by stating that comprehensive care in 
gynecological cancer surviving women should be 
handled by a multidisciplinary team of specialists in 
order to improve overall quality of life in these patients. 
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